AT502717A1 - Pharmazeutische verwendung einer verbindung - Google Patents
Pharmazeutische verwendung einer verbindung Download PDFInfo
- Publication number
- AT502717A1 AT502717A1 AT0183305A AT18332005A AT502717A1 AT 502717 A1 AT502717 A1 AT 502717A1 AT 0183305 A AT0183305 A AT 0183305A AT 18332005 A AT18332005 A AT 18332005A AT 502717 A1 AT502717 A1 AT 502717A1
- Authority
- AT
- Austria
- Prior art keywords
- psidium
- extract
- plant
- cattleianum
- medicament
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 22
- 239000000284 extract Substances 0.000 claims description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 241000508269 Psidium Species 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 15
- 244000169711 Psidium cattleianum Species 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 235000013929 Psidium pyriferum Nutrition 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 235000006978 Psidium cattleianum Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 244000077991 Psidium molle Species 0.000 claims description 10
- 235000000742 Psidium molle Nutrition 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- ALRFYJWUVHBXLV-UHFFFAOYSA-N guaijaverin Natural products OC1COC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O ALRFYJWUVHBXLV-UHFFFAOYSA-N 0.000 claims description 8
- PZZRDJXEMZMZFD-IEGSVRCHSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O PZZRDJXEMZMZFD-IEGSVRCHSA-N 0.000 claims description 7
- 235000012087 Psidium araca Nutrition 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 3
- 235000019520 non-alcoholic beverage Nutrition 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 235000020939 nutritional additive Nutrition 0.000 claims description 2
- 240000001679 Psidium guajava Species 0.000 claims 5
- 235000015126 Psidium littorale Nutrition 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- BDCDNTVZSILEOY-UXYNSRGZSA-N avicularin Chemical compound O[C@@H]1[C@@H](O)[C@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-UXYNSRGZSA-N 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 30
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 244000236580 Psidium pyriferum Species 0.000 description 8
- 229920005989 resin Polymers 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 5
- 239000002532 enzyme inhibitor Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003795 desorption Methods 0.000 description 4
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 4
- 239000012622 synthetic inhibitor Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000011957 flavonols Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- -1 flavonol compounds Chemical class 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000159454 Myrcia multiflora Species 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940008523 psidium guajava extract Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003085 retinopathic effect Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0183305A AT502717A1 (de) | 2005-11-09 | 2005-11-09 | Pharmazeutische verwendung einer verbindung |
| US12/093,264 US20090186110A1 (en) | 2005-11-09 | 2006-11-08 | Guava extract |
| PCT/AT2006/000454 WO2007053865A1 (en) | 2005-11-09 | 2006-11-08 | Pharmaceutical use of a compound |
| JP2008539185A JP5717317B2 (ja) | 2005-11-09 | 2006-11-08 | 化合物の医薬品的使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0183305A AT502717A1 (de) | 2005-11-09 | 2005-11-09 | Pharmazeutische verwendung einer verbindung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT502717A1 true AT502717A1 (de) | 2007-05-15 |
Family
ID=37876593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0183305A AT502717A1 (de) | 2005-11-09 | 2005-11-09 | Pharmazeutische verwendung einer verbindung |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090186110A1 (enExample) |
| JP (1) | JP5717317B2 (enExample) |
| AT (1) | AT502717A1 (enExample) |
| WO (1) | WO2007053865A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173975A (zh) * | 2014-08-25 | 2014-12-03 | 河南科技大学第一附属医院 | 一种用于治疗糖尿病的中药组合物 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080293644A1 (en) * | 2007-04-27 | 2008-11-27 | Thomas Eidenberger | Guava extract |
| JP2010105922A (ja) * | 2008-10-28 | 2010-05-13 | Uha Mikakuto Co Ltd | Ｌｏｘ−１アンタゴニスト作用剤 |
| CA2823534C (en) * | 2010-12-28 | 2018-09-11 | Mary Kay Inc. | Topical composition comprising a psidium guajava extract and a kunzea ericoides extract for providing sebum control and treating acne |
| US8877259B2 (en) | 2012-02-09 | 2014-11-04 | Mary Kay Inc. | Cosmetic formulation |
| CN103565928A (zh) * | 2013-11-01 | 2014-02-12 | 华南农业大学 | 一种番石榴降糖活性组分、制备方法及用途 |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| EP3413727B1 (de) | 2016-02-10 | 2025-09-17 | PM-International AG | Nahrungsergänzungsmittel enthaltend guaijaverin und phloretin zur reduzierung und/oder hemmung einer intestinalen glucose-resorption |
| DE102016102265A1 (de) | 2016-02-10 | 2017-08-10 | Pm-International Ag | Zusammensetzung zur Reduzierung und/oder Hemmung einer intestinalen Glucose-Resorption, Nahrungsergänzungsmittel, Verwendung der Zusammensetzung und Verfahren zur Herstellung des Nahrungsergänzungsmittels |
| DE102016102271A1 (de) | 2016-02-10 | 2017-08-10 | Pm-International Ag | Zusammensetzung zur Reduzierung und/oder Hemmung einer intestinalen Glucose-Resorption, Nahrungsergänzungsmittel, Verwendung der Zusammensetzung und Verfahren zur Herstellung des Nahrungsergänzungsmittels |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| EP3829612A1 (de) * | 2018-08-02 | 2021-06-09 | PM-International AG | Gänseblümchenextrakt |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) * | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) * | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| JPS6056923A (ja) * | 1983-09-06 | 1985-04-02 | Bizen Kasei Kk | グアバ葉エキスの抽出方法 |
| JPS6137731A (ja) * | 1984-07-31 | 1986-02-22 | Bizen Kasei Kk | グアバ葉エキスを有効成分とする経口糖尿病薬 |
| US5163899A (en) * | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| JPS63283563A (ja) * | 1987-05-18 | 1988-11-21 | Morishige Okinaga | グァバ茶の製造方法 |
| US5312325A (en) * | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) * | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5008110A (en) * | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) * | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| CA2031376A1 (en) * | 1989-12-04 | 1991-06-05 | Bahram Farhadieh | Single layer transdermal drug administration system |
| US5352456A (en) * | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| ATE132381T1 (de) * | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| JP3193441B2 (ja) * | 1992-03-09 | 2001-07-30 | 御木本製薬株式会社 | 美白化粧料 |
| JP4109731B2 (ja) * | 1997-01-23 | 2008-07-02 | 備前化成株式会社 | 改良グアバ葉エキス抽出法 |
| EP1214308A2 (en) * | 1999-09-23 | 2002-06-19 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Novel flavonoids |
| JP2003528135A (ja) * | 2000-03-31 | 2003-09-24 | プロバイオドラッグ アーゲー | 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法 |
| ES2173047B1 (es) * | 2001-03-21 | 2004-01-01 | Aplicaciones Farmacodinamicas | Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii |
| KR100443264B1 (ko) * | 2001-06-07 | 2004-08-04 | 한국생명공학연구원 | 구아바로부터 얻은 단백질 타이로신 탈인산화 효소 １ｂ 저해용 활성분획 추출물 |
| US20060188590A1 (en) * | 2005-01-05 | 2006-08-24 | Mitsunori Ono | Compositions for treating diabetes or obesity |
-
2005
- 2005-11-09 AT AT0183305A patent/AT502717A1/de not_active Application Discontinuation
-
2006
- 2006-11-08 WO PCT/AT2006/000454 patent/WO2007053865A1/en not_active Ceased
- 2006-11-08 US US12/093,264 patent/US20090186110A1/en not_active Abandoned
- 2006-11-08 JP JP2008539185A patent/JP5717317B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173975A (zh) * | 2014-08-25 | 2014-12-03 | 河南科技大学第一附属医院 | 一种用于治疗糖尿病的中药组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5717317B2 (ja) | 2015-05-13 |
| JP2009514901A (ja) | 2009-04-09 |
| WO2007053865A9 (en) | 2007-07-12 |
| US20090186110A1 (en) | 2009-07-23 |
| WO2007053865A1 (en) | 2007-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3006215C2 (enExample) | ||
| DE69012566T2 (de) | Verfahren zur Gewinnung von Carnosäure. | |
| DE60109938T2 (de) | Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels | |
| DE60110438T2 (de) | Zusammensetzungen enthaltend stilbenoide mit einer hypoglykämischen wirkung | |
| US20020040052A1 (en) | Method for neurite outgrowth | |
| HK1199823A1 (zh) | 美拉德反应抑制剂 | |
| DE112009005072T5 (de) | Verfahren zur Herstellung eines Extrakts von Gynostaema pentaphyllum mit erhöhten Gehalten an Damulin A und Damulin B sowie pharmazeutische Zusammensetzungen davon zur Behandlung des metabolischen Syndroms | |
| CA2682143C (en) | Method for extracting secoisolariciresinol and dihydroquercetin from wood | |
| DE60002081T2 (de) | Ein komplex enthaltend lignan, phenolische und aliphatische stoffe isoliert von flax und verfahren zur herstellung | |
| DE19756848C2 (de) | Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen | |
| JP5717317B2 (ja) | 化合物の医薬品的使用 | |
| KR101350433B1 (ko) | 은행나무 추출물로부터 살충제를 제거하는 방법，및 상기 방법에 의해 수득가능한 추출물 | |
| DE102009022414B4 (de) | Antibakterielle Verwendung eines Extrakts aus Morus australis Poir. und der Verbindung Kuwanon H | |
| US6942882B2 (en) | Hepatic disorder suppressant | |
| DE60112482T2 (de) | Verbindungen mit antioxidierender Wirkung, diese enthaltende Zusammensetzungen zur Nahrungsmittelergänzung sowie Verfahren zu deren Herstellung | |
| US6589573B2 (en) | Xanthine oxidase inhibitor and method for producing the same | |
| JP5092122B2 (ja) | 新規ステロイド配糖体、ｎｇｆ関連活性物質、その製造方法及び探索方法、並びに脳機能障害予防薬 | |
| JP5441433B2 (ja) | カムカムフルーツ果汁含有肝機能改善剤 | |
| DE68906248T2 (de) | Antagonisten fuer den platelet-aktivierungsfaktor, phomactine genannt, ihre herstellung und verwendung. | |
| DE2609533A1 (de) | Verfahren zur extraktion von wirkstoffen, insbesondere von heterosidestern, der kaffeesaeure, sowie diese verbindungen enthaltende arzneimittel | |
| DE4320889C2 (de) | Neue extrahierte Substanz mit Anti-HIV-Aktivität | |
| KR100458003B1 (ko) | 방울비짜루(남옥대)로부터 분리한 신규 항암활성 화합물 및 그 정제방법 | |
| DE19732855C2 (de) | Spezieller Soja-Extrakt, dessen Herstellung, diesen enthaltende Formulierungen und deren Verwendung für die Prävention oder Behandlung von Krebs | |
| KR20040074249A (ko) | 두충잎의 품질 검정방법 | |
| US20190374500A1 (en) | Process for Preparing Water Soluble Azadiractin Powder Formulation with In-Built and External Inclusion Complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REJ | Rejection |
Effective date: 20160515 |